Compare Amphastar Pharmaceuticals Inc (AMPH) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Fidelity National Information Servcs Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.04 (market cap $868.62M), while Fidelity National Information Servcs Inc trades at $42.9 (market cap $22.05B). The key difference: Fidelity National Information Servcs Inc is far larger — about 25.4× Amphastar Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | FIS | |
|---|---|---|
Market Cap | $868.62M | $22.05B |
Sector | Health | Technology |
52-Week High | $30.81 | $72.77 |
52-Week Low | $16.87 | $37.72 |
Enterprise Value | $1.27B | $42.56B |
Dividend Yield | — | 4.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.98, down 1.62% today, with a bullish technical signal supported by moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
The outlook is balanced with analyst consensus leaning Hold (66.67%) amid regulatory scrutiny and competitive pressures. Near-term catalysts include pipeline developments, but risks from FDA warnings and generic drug tariff uncertainties warrant caution. Cash flow trends improved with 2026 net cash flow projected at $36 million.
FIS trades at $42.10, down 0.96% with bearish technical signals. The company shows improving fundamentals with Q2 2026 earnings beat and 5.3% revenue growth, though it lowered full-year guidance. Valuation appears attractive with P/E of 6.57 and P/S of 1.82. Recent expansion into APAC markets and treasury software recognition provide growth catalysts. Cash flow improved significantly from 2025's negative $1.35B to projected positive $188M for 2026.
FIS presents a mixed outlook with strong banking solutions growth offset by capital markets weakness. The 19% upside to consensus price target of $50.18 offers potential, but execution risks remain given the guidance reduction. Investors should weigh the attractive valuation against operational challenges in achieving sustained profitability improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
